Audrey Sternberg

CancerNetwork spoke with AmerisourceBergen's Lisa Harrison, RPh, about how the new Enhancing Oncology Model and medically integrated dispensing factor into combating health disparities.

Results from a Korean study presented at 2022 IGCS showed that the level of CA-125 at different timepoints during neoadjuvant chemotherapy may help clinicians decide which patients with high-grade serous ovarian cancer should undergo interval debulking surgery.

At the 5-year mark, overall survival was improved with xevinapant plus standard chemoradiotherapy vs matched placebo in locally advanced head and neck squamous cell carcinoma.

Results of the phase 3 ARIEL4 trial comparing rucaparib vs chemotherapy for patients with relapsed ovarian cancer and deleterious BRCA1/2 mutations were presented at 2022 ESMO and raised questions about optimal sequencing of PARP inhibitors in this setting.

Following data presented from the phase 1/2 CodeBreak 100 and CodeBreak 101 trials, a regimen consisting of sotorasib with a safety lead-in followed by concurrent pembrolizumab will be further explored in patients with KRAS G12C–mutant non–small cell lung cancer.

Supported by data from an ongoing phase 2 trial, the ROS1 inhibitor taletrectinib was granted breakthrough therapy designation for the treatment of certain patients with advanced or metastatic ROS1-positive non–small cell lung cancer.

At the 2022 American Society of Clinical Oncology Annual meeting, Robert H. Vonderheide, MD, DPhil, and colleagues from the Parker Institute for Cancer Immunotherapy present research into biosignatures of survival with different chemoimmunotherapy regimens for pancreatic ductal adenocarcinoma.

Based on results of a phase 1/2 trial of single-agent mosunetuzumab in B-cell malignancies, the agent was granted priority review by the FDA for the treatment of relapsed/refractory follicular lymphoma.

Data presented at the 2022 European Hematology Association Congress demonstrated potential utility of the bispecific antibody RG6234 in a previously treated cohort of patients with multiple myeloma.

Dabrafenib plus trametinib may now be used to treat patients with BRAF V600E–positive solid tumors who have no suitable alternative treatment options following its approval by the FDA.

Data from the SPOTLIGHT trial indicate agreement among trained PET readers was highly concordant with use of 18F-rhPSMA-7.3 imaging for recurrent prostate cancer.

The combination of quizartinib plus chemotherapy yielded better survival outcomes vs chemotherapy alone in the frontline setting of FLT3-ITD-positive acute myeloid leukemia.

At the Leonard B. Kahn Institute for Head & Neck Cancer at Carol G. Simon Cancer Center at Morristown Medical Center, clinicians rely on colleagues from different specialty backgrounds to provide their patients the most comprehensive care management of head and neck cancer.

Patients with acquired ESR1 mutations after disease progression and post-treatment for locally advanced or metastatic estrogen receptor–positive, HER2-negative breast cancer may benefit from treatment with lasofoxifene in combination with abemaciclib.

A neoadjuvant and postsurgical treatment regimen involving ruxolitinib and chemotherapy appeared to boost progression-free survival in patients with stage III and IV ovarian cancer.

Factors associated with early discontinuation of adjuvant abemaciclib for hormone receptor—positive, HER2-negative, node-positive high-risk early breast cancer inform future treatment monitoring.

In a MET-unselected population of PD-L1–positive non–small cell lung cancer, the addition of capmatinib to pembrolizumab did not lead to more responses but increased toxicity.

Data from the phase 2 IFM 2018-04 trial support the use of daratumumab, carfilzomib, lenalidomide, and dexamethasone coupled with tandem autologous stem cell transplant in eligible patients with high-risk multiple myeloma.

The combination of pembrolizumab plus ramucirumab resulted in better overall survival compared with the standard of care regimens despite similar response rates, according to results of a Lung-MAP substudy presented at 2022 ASCO.

Semi-structured qualitative interviews revealed that patients undergoing allogeneic hematopoietic stem cell transplant could benefit from peer support prior to and during transplantation.

Numerous renal and cardiac indices as well as quality-of-life measures were improved with a comprehensive vs routine nursing care model.

Based on the results of the AZA-JMML-001 trial, the FDA has approved azacitidine for use in newly diagnosed juvenile myelomonocytic leukemia.

Response to idecabtagene vicleucel for patients with pretreated multiple myeloma did not appear to be influenced by baseline body mass index.

Patients with chronic graft-vs-host disease who were administered full series of the SARS-CoV-2 vaccine displayed varied immune responses, regardless of baseline characteristics.

Bone marrow fibrosis improvement and variant allele frequency reduction observed with navitoclax plus ruxolitinib for patients with previously treated myelofibrosis may suggest disease modification.

Biomarker analysis and studies of pharmacokinetics, pharmacodynamics, and T-cell composition show certain T-cell characteristics are linked with outcomes and toxicity with axicabtagene ciloleucel in large B-cell lymphoma.

Updated data from a pivotal trial that led to the approval of zanubrutinib for the treatment of patients with relapsed or refractory mantle cell lymphoma appears to highlight persistent benefit.

In a poster presentation from Society of Gynecologic Oncology 2022 Annual Meeting, investigators led by Cara Mathews, MD, aimed to determine the benefit of dostarlimab vs standard-of-care doxorubicin for advanced recurrent endometrial cancer.

Based on results of the ZUMA-7 trial, the FDA approved axicabtagene ciloleucel for the treatment of certain patients with large B-cell lymphoma who received chemoimmunotherapy in the frontline setting.

At SGO 2022, CancerNetwork® spoke with Jyoti Mayadev, MD, about a clinical trial involving immune priming with the PD-L1 inhibitor atezolizumab for patients with locally advanced cervical cancer.